To investigate the relationship between esophageal motility and GI hormones in patients suffering from gastroesophageal reflux disease (GERD), the esophageal motility in 20 GERD patients with esophagitis and 25 GERD patients without esophagitis was examined by means of SGY-3 Digestive Tract Motility Measuring Instrument. Meanwhile,Serum gastrin,motilin,glucagon,estradiol were measured with RIA.The data from 15 healthy volunteers served as control.The results showed that ①GERD patients without esophagitis had lower LESP(2 12?1 00kPa) than control(3 23?0 72kPa P

Objective To evaluate the changes in esophageal pressure and 24h pH on the pathogenesis of esophagitis by means of a multivariate logistic regression analysis of obtained values. Methods Monovariate comparison of parameters from 24h ambulatory esophageal pH measurements and esophageal manometry between two groups of gastro-esophageal reflux disease (GERD) patients, including 45 with esophagitis, 40 without esophagitis, and 42 healthy controls. Multivariate logistic regression analysis of parameters obtained was carried out. Results All parameters of DeMeester-Johson score were significantly higher in esophagitis than those of without esophagitis. The composite scores were 113.29?26.73 and 42.66?11.25, respectively (P

Twenty four hour esophageal pH monitoring was performed in 79 ambulatary patients suffering from reflux symptoms, in whom 40 with esophagitis and 39 without. The aim of the study was to investigate the correlation between reflux symptoms and objective occurrence of acid reflux in the patients with and without esophagitis. The results showed that the six parameters of Johnson/DeMeester score were significantly higher for esophagitis than endoscopic negative patients. The composite score were (85.85?15 10) and (26 20?9 25), respectively( P

0.05).The incidence of adverse events was low and similar in each group. CONCLUSIONS Rifaximin is a safe and effective alternative to ciprofloxacin in the treatment of acute infectious diarrhea in adults.

Objective To investigate the efficacy and safety of Minilase-S on patients with dyspepsia.Methods A randomized,placebo-controlled,double blind and multicenter study was conducted.Two hundred and forty patients with dyspepsia symptoms(anorexia,fullness,abdominal discomfort and distension)were collected according to total symptom scores over 20 with visual analog scales.Each patient was randomly received either Minilase-S(2 capsules t.i.d)or placebo(2 capsules t.i.d)for 2 weeks.The symptoms scores were evaluated at treatment week 1,week 2,and 1 week after discontinued therapy.Results Two hundred and sixteen patients(105 patients in Minilase group and 111 patients in placebo group)finished the study.There was no difference in demographic data,anorexia,fullness,discomfort and distension score and the total symptom score between two groups.However,at treatment week 1,week 2 and 1 week after discontinued therapy,symptoms and total symptom score were significantly decreased in Minilase-S group compared to placebo group(all P value＜0.05).The total effective rates in treatment week 1,week 2 and 1 week after discontinued therapy were 64.76%,77.05%and 66.99%,respectinely,which were higer that those in placebo group(27.93%,37.84% and 29.36%,respectively)(P＜0.05).There was no severe side effects in both Minilase-S and placebo groups.Conclusions Minilase-S can significantly improve symptoms in patients with dyspepsia,which may be as one choice in the management of dyspepsia or in combined therapy.